Get started
Author

Raul Chertkoff

Observed names: Chertkoff, R, Chertkoff, Raul, R. Chertkoff
OpenAlex ID: A5091262663
The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statement
2003 · T. M. Cox, J. M. F. G. Aerts, et al. · Journal of Inherited Metabolic Disease · 238
Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease
2011 · Ari Zimran, Einat Brill-Almon, et al. · Blood · 206
PDF
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial
2019 · Raphael Schiffmann, Ozlem Goker‐Alpan, et al. · Journal of Inherited Metabolic Disease · 148
PDF
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase
2014 · Gregory M. Pastores, Milan Petakov, et al. · Blood Cells Molecules and Diseases · 61
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
2023 · Eric L Wallace, Ozlem Goker-Alpan, et al. · Journal of Medical Genetics · 56
PDF
Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story
2017 · Bonita Rup, Sari Alon, et al. · PLoS ONE · 56
PDF
Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase
2016 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Blood Cells Molecules and Diseases · 44
PDF
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
2023 · Aleš Linhart, Gabriela Dostálová, et al. · Orphanet Journal of Rare Diseases · 40
PDF
Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease
2012 · L. van Dussen, A. Zimran, et al. · Blood Cells Molecules and Diseases · 37
Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease
2014 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Blood Cells Molecules and Diseases · 35
PDF
Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
2016 · Gregory M. Pastores, Suma P. Shankar, et al. · American Journal of Hematology · 31
PDF
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease
2023 · Derralynn Hughes, Derlis Gonzalez, et al. · Genetics in Medicine · 29
PDF
Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease
2016 · Ari Zimran, Gloria Durán, et al. · Blood Cells Molecules and Diseases · 29
PDF
Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis
2020 · Einat Almon, Yoseph Shaaltiel, et al. · Journal of Clinical Gastroenterology · 28
An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy
2017 · Einat Almon, Tawfik Khoury, et al. · Journal of Immunological Methods · 25
Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
2016 · Ari Zimran, Gloria Durán, et al. · American Journal of Hematology · 24
PDF
6. Novel enzyme replacement therapy for Gaucher disease: On-going phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells
2008 · David Aviezer, Einat Almon-Brill, et al. · Molecular Genetics and Metabolism · 24
A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
2024 · Myrl Holida, Aleš Linhart, et al. · Journal of Inherited Metabolic Disease · 22
Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R
2015 · Jacob Atsmon, Einat Brill-Almon, et al. · Toxicology and Applied Pharmacology · 22
Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model
2010 · Luc Bracoud, Harris Ahmad, et al. · Blood Cells Molecules and Diseases · 22
8. Novel enzyme replacement therapy for Gaucher disease: Ongoing Phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells
2009 · David Aviezer, Einat Almon-Brill, et al. · Molecular Genetics and Metabolism · 18
National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model
2006 · Irina Kesselman, Deborah Elstein, et al. · Blood Cells Molecules and Diseases · 18
9. Novel enzyme replacement therapy for Gaucher disease: Phase III pivotal clinical trial with plant cell expressed recombinantglucocerebrosidase (prGCD) – taliglucerase alpha
2010 · David Aviezer, Einat Almon-Brill, et al. · Molecular Genetics and Metabolism · 13
Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease
2015 · Richat Abbas, Glen Park, et al. · PLoS ONE · 11
PDF
Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study
2020 · Ales Linhart, Gabriela Dostalova, et al. · Molecular Genetics and Metabolism · 8
Works count: 103
Citation count: 1,328
H-index: 20
I10-index: 24
Year
Topic
Type